In this review:
Updated McDonald criteria (2010) for diagnosing MS
Natalizumab improves walking and upper-limb disability in patients with SPMS
Natalizumab during pregnancy
CIS: prognosis after 30 years
SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS
Ozanimod vs interferon β-1a: clinical and MRI results of RADIANCE part B trial
Timing of high-efficacy DMTs for RRMS
Effect of ocrelizumab vs IFN β-1a on visual outcomes in the OPERA studies
Predictors of an opicinumab treatment effect in the SYNERGY trial
PARADIGMS: fingolimod vs IFN β-1a in paediatric MS
Please login below to download this issue (PDF)